Inhibitors of c-jun-N-Terminal Kinase (JNK)
Philip LoGrasso and Theodore Kamenecka
Pages 755-766 (12)
Inhibitors of c-jun-N-Terminal Kinase (JNK) have many potential therapeutic indications ranging from neurodegenerative disease, to metabolic disorders, inflammation, cardiovascular disease, and cancer. This overview will highlight biological inhibitors such as JNK-interacting protein (JIP) as well as small molecule inhibitors from various structural classes including, aminopyrimidines and indazoles.
c-jun-N-Terminal Kinase (JNK), mitogen activated protein (MAP), benzothiazole pyrimidines, benzothien-2-yl amides, indazoles, aminopyrimidines, aminopyridines, quinolines
Department of Molecular Therapeutics and Drug Discovery, The Scripps Research Institute, 5353 Parkside Drive, Jupiter, FL 33458, USA.